The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)
Abstract
Objective: The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease‐modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated success in reducing AS disease activity in a limited number of clinical trials. The objective of this multicenter, randomized, placebo‐controlled study was to evaluate the efficacy and safety of infliximab in patients with AS. Methods: Patients were randomly assigned to receive infusions of placebo or 5 mg/kg infliximab at weeks 0, 2, 6, 12, and 18. Efficacy was assessed using the ASsessment in Ankylosing Spondylitis (ASAS) International Working Group criteria, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), night pain, patient's global assessment, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Metrology Index (BASMI), chest expansion, the Mander enthesis index, the total swollen joint index, the C‐reactive protein level, and the Short Form 36 (SF‐36) health survey questionnaire. The primary end point in this study was the proportion of patients with a 20% improvement response according to the ASAS International Working Group criteria (ASAS20 responders) at week 24. Results: Of the 357 patients screened, 201 were assigned to receive 5 mg/kg infliximab and 78 were assigned to receive placebo. After 24 weeks, 61.2% of patients in the infliximab group were ASAS20 responders compared with 19.2% of patients in the placebo group ( P < 0.001). Clinical benefit was observed in patients receiving infliximab as early as week 2 and was maintained over the 24‐week study period. Patients receiving infliximab also showed significant improvements in the BASDAI, BASFI, BASMI, chest expansion, and physical component summary score of the SF‐36. Adverse events were reported by 82.2% of patients receiving infliximab and by 72.0% of patients receiving placebo; however, most adverse events in both treatment groups were mild or moderate in severity. Conclusion: Infliximab was well tolerated and effective in a large cohort of patients with AS during a 24‐week study period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluation of Diagnostic Criteria for Ankylosing Spondylitis
Linden, S. V. D., Valkenburg, H. A., & Cats, A. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270401 · Cited by 5,697
(1994) · Medical Entomology and Zoology · Cited by 4,156
Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Călin, A. (1994) · PubMed · Cited by 3,241
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Self-citationMaini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Călin, A., Garrett, S., Whitelock, H., Kennedy, L. G., O'Hea, J., MALLORIE, P. A., & Jenkinson, T. (1994) · PubMed · Cited by 1,834
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-70 · Cited by 1,833
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-lhle, E., Kellner, H., Krause, A., Schneider, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08215-6 · Cited by 1,261
Self-citationINFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.
Jenkinson, T., MALLORIE, P. A., Whitelock, H., KENNEDY, L. G., Garrett, S. L., & Călin, A. (1994) · PubMed · Cited by 981
Davis, J. C., Van Der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D. O., Kivitz, A., Fleischmann, R., Inman, R., Tsuji, W., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11325 · Cited by 754
Self-citationTreatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α
Gorman, J. D., Sack, K. E., & Davis, J. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012664 · Cited by 704
Braun, J., Bollow, M., Neure, L., Seipelt, E., Seyrekbasan, F., Herbst, H., Eggens, U., Distler, A., & Sieper, J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380407 · Cited by 690
Self-citationAssessment of enthesitis in ankylosing spondylitis
Heuft-Dorenbosch, L., Spoorenberg, A., van Tubergen, A., Landewé, R., van der Tempel, H., Mielants, H., Dougados, M., & van der Heijde, D. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.2.127 · Cited by 683
Self-citationAntoni, C. E., Kavanaugh, A., Kirkham, B., Tutuncu, Z., Burmester, G. R., Schneider, U., Furst, D. E., Molitor, J., Keystone, E., Gladman, D., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20967 · Cited by 640
Anderson, J. J., Baron, G., Van Der Heijde, D., Felson, D. T., & Dougados, M. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200108)44:8<1876::aid-art326>3.0.co;2-f · Cited by 606
Self-citationWare, J. E., Gandek, B., Kosinski, M., Aaronson, N. K., Apolone, G., Brazier, J., Bullinger, M., Kaasa, S., Leplège, A., Prieto, L., et al. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00108-5 · Cited by 560
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Furst, D., Weisman, M. H., St.Clair, E. W., Keenan, G. F., van der Heijde, D., Marsters, P. A., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20159 · Cited by 514
Self-citationBrandt, J., Haibel, H., Cornely, D., Golder, W., Gonzalez, J., Reddig, J., Thriene, W., Sieper, J., & Braun, J. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200006)43:6<1346::aid-anr18>3.0.co;2-e · Cited by 485
Self-citationTREATMENT OF ANKYLOSING SPONDYLITIS BY INHIBITION OF TUMOR NECROSIS FACTOR a
Orman, D., Enneth, K., Ack, E. S., Ohn, J., & Avis, C. D. (2002) · Cited by 470
Rudwaleit, M., Listing, J., Brandt, J., Braun, J., & Sieper, J. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.016386 · Cited by 439
Self-citationBraun, J., Baraliakos, X., Golder, W., Brandt, J., Rudwaleit, M., Listing, J., Bollow, M., Sieper, J., & van der Heijde, D. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10883 · Cited by 397
Self-citationVan den Bosch, F., Kruithof, E., Baeten, D., Herssens, A., de Keyser, F., Mielants, H., & Veys, E. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.511 · Cited by 352
Van den Bosch, F., Kruithof, E., Baeten, D., De Keyser, F., Mielants, H., & Veys, E. M. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.6.428 · Cited by 288
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Burmester, G., Golder, W., Gromnica‐Ihle, E., Kellner, H., Schneider, M., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11104 · Cited by 264
Self-citationStudies with an enthesis index as a method of clinical assessment in ankylosing spondylitis.
Mander, M., Simpson, J. M., McLellan, A., Walker, D., Goodacre, J. A., & Dick, W. C. (1987) · Annals of the Rheumatic Diseases · doi:10.1136/ard.46.3.197 · Cited by 256
Baeten, D., Kruithof, E., Van den Bosch, F., Van den Bossche, N., Herssens, A., Mielants, H., De Keyser, F., & Veys, E. M. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.9.829 · Cited by 186
Maksymowych, W. P., Jhangri, G. S., Lambert, R. G. W., Mallon, C., Buenviaje, H., Pedrycz, E., Luongo, R., & Russell, A. S. (2002) · PubMed · Cited by 144
Braun, J., & Sieper, J. (2002) · Arthritis Research · doi:10.1186/ar592 · Cited by 124
Self-citationKruithof, E., den Bosch, F. V., Baeten, D., Herssens, A., Keyser, F. D., Mielants, H., & Veys, E. M. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.3.207 · Cited by 121
Zou, J., Rudwaleit, M., Brandt, J., Thiel, A., Braun, J., & Sieper, J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10847 · Cited by 103
Self-citationConsequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade.
Wagner, C. L., Schantz, A., Barnathan, E. S., Olson, A., Mascelli, M. A., Ford, J., Damaraju, L. V., Schaible, T., Maini, R. N., & Tcheng, J. E. (2003) · PubMed · Cited by 85
Socioeconomic consequences of ankylosing spondylitis
Boonen, A. E. R. C. H. (2002) · Research Publications (Maastricht University) · doi:10.26481/dis.20021218ab · Cited by 69
Zhang, X., Aubin, J. E., & Inman, R. D. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200307000-00004 · Cited by 52
Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs.
van der Horst-Bruinsma, I. E., Clegg, D. O., & Dijkmans, B. A. C. (2002) · PubMed · Cited by 37
Self-citationNovel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides
Braun, J., & van der Heijde, D. M. F. M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.7.1097 · Cited by 33
Self-citationWarrington (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200101)44:1 · Cited by 2
Cited by
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Braun, J., & Sieper, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60635-7 · Cited by 1,806
Self-citation2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
van der Heijde, D., Ramiro, S., Landewé, R., Baraliakos, X., Van den Bosch, F., Sepriano, A., Regel, A., Ciurea, A., Dagfinrud, H., Dougados, M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210770 · Cited by 1,568
Self-citationSieper, J., & Poddubnyy, D. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31591-4 · Cited by 1,333
Self-citationSecukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., Deodhar, A., Porter, B., Martin, R., Andersson, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505066 · Cited by 1,029
Self-citation
Metadata
- Authors
- van der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., DeWoody, K., Williamson, P., & Braun, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-02
- Volume
- 52
- Issue
- 2
- Pages
- 582-591
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2081388746
- Cited by
- 860
- References
- 37
- FWCI
- 36.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.